Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Over the past several decades, the incidence of early-onset cancers, often defined as
cancers diagnosed in adults< 50 years of age, in the breast, colorectum, endometrium …
cancers diagnosed in adults< 50 years of age, in the breast, colorectum, endometrium …
Epidemiology, staging, and management of multiple myeloma
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
H Mei, C Li, H Jiang, X Zhao, Z Huang, D Jin… - Journal of Hematology & …, 2021 - Springer
Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …
Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
BSA‐AIE nanoparticles with boosted ROS generation for immunogenic cell death immunotherapy of multiple myeloma
Z Liu, J Zhang, H Liu, H Shen, N Meng, X Qi… - Advanced …, 2023 - Wiley Online Library
The main obstacle of multiple myeloma (MM) therapy is the compromised immune
microenvironment, which leads to MM relapses and extramedullary disease progression. In …
microenvironment, which leads to MM relapses and extramedullary disease progression. In …
Prevalence of smoldering multiple myeloma based on nationwide screening
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma.
Here we define the epidemiological characteristics of SMM in the general population in …
Here we define the epidemiological characteristics of SMM in the general population in …
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
F Mazahreh, L Mazahreh, C Schinke… - Blood …, 2023 - ashpublications.org
The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple
myeloma (MM) is showing early promising overall response rates in heavily pretreated …
myeloma (MM) is showing early promising overall response rates in heavily pretreated …
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …
[HTML][HTML] Multiple myeloma: the (r) evolution of current therapy and a glance into the future
KC Anderson - Haematologica, 2020 - ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …